NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 9th July 2024

**Location:** Via London Office and Zoom

## Attendees

Committee members present

1. Dr James Fotheringham (Vice-chair) Present for all items
2. Dr Peter Baker-Gulliver Present for all items
3. Dr Ian Bernstein Present for all items
4. Dr Craig Buckley Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Patrick De Barr Present for all items
7. Dr Justin Daniels Present for all items
8. Ana Duarte Present for all items
9. Dr Steve Edwards Present for all items
10. Mohamad Farhat Items 1.1 to 4.1.3
11. Mario Ganau Present for all items
12. Professor G.J. Melendez-Torres Present for all items
13. Hugo Pedder Present for all items
14. Becky Pennington Present for all items
15. Dr Ravi Ramessur Present for all items
16. Dr Mohit Sharma Present for all items
17. Alan Thomas Present for all items
18. Jaqueline Tomlinson Present for all items

NICE staff (key players) present

Ian Watson, Associate Director Items 1.1 to 4.2.2

Leena Issa, Project Manager Items 1.1 to 4.2.2

Christian Griffiths, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Samuel Slayen, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Janet Robertson, Associate Director Items 5.1 to 5.2.2

Jennifer Upton, Project Manager Items 5.1 to 5.2.2

Albany Chandler, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Sharlene Ting, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Robert Wolff, Kleijnen Systematic Reviews Ltd Items 1.1 to 4.1.3

Bram Ramaekers, Kleijnen Systematic Reviews Ltd Items 1.1 to 4.1.3

Felix Achana, Warwick Evidence Items 5.1 to 5.1.3

Yen-Fu Chen, Warwick Evidence Items 5.1 to 5.1.3

Henry Nwankwo, Warwicl Evidence Items 5.1 to 5.1.3

Ayesha Ali, NHS England Commissioner Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Sanjay Popat, Clinical expert, nominated by Astrazeneca and British Thoracic Oncology Group Items 1.1 to 4.1.3

Michael Addelman, Patient expert, nominated by NICE Items 1.1 to 4.1.3

Peter Clark, CDF Clinical Lead, NHSE Items 1.1 to 4.2.2

Prof Richard Thompson, Clinical Expert, nominated by Mirum Pharmaceuticals

Items 5.1 to 5.1.3

Caitlin Mullholland, Patient Expert, nominated by Children’s Liver Disease Foundation

Items 5.1 to 5.1.3

Mel Fernadez, Patient Expert, nominated by Children’s Liver Disease Foundation

Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Fiona MacPherson Smith, Radha Todd, Dominic Pivonka, Min Ven Teo and Richard Ballerand.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 11th June.

### Appraisal of [Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11197)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11197).
     3. The Chair led a discussion This information was presented to the committee by James Fotheringham (lay), Mohammed Farhat (clinical) and Hugo Pedder.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached .
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11197>.

### Appraisal of Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Mirum Pharma.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10832).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Mario Ganau (lay), Becky Pennington (clinical) and James Fotheringham (cost).
  2. Part 2 – Closed session (company representatives, patient, clinical and professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10832>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 13th August 2024 and will start promptly at 9:00am.